Results 241 to 250 of about 33,638 (296)

Clinical and Immune Effects of Peri-Transplantation JAK Inhibition for Myelofibrosis. [PDF]

Am J Hematol
Rathje K, Gagelmann N, Badbaran A, Langebrake C, Dadkhah A, Richter J, Massoud R, Schäfersküpper M, Marquard FE, Oechsler S, Klyuchnikov E, Rudolph I, Heidenreich S, Niederwieser C, Lueck C, Janson D, Wolschke C, Fehse B, Ayuk F, Kröger N.   +19 more
europepmc   +1 more source

Clinical features and treatment of newly diagnosed multiple myeloma with secondary myelofibrosis: a retrospective study. [PDF]

Ther Adv Hematol
Xu H, Xu Y, Wang M, Mao C, Huang J, Li T, Gao Y, Liu S, Zhou J, Zhang Y, Feng X.   +10 more
europepmc   +1 more source

Case report: Successful use of ruxolitinib to treat interstitial pneumonia as an unusual primary presentation in primary myelofibrosis-two birds with one stone. [PDF]

Front Oncol
Xiao P, Dong Z, Wang Q, Su J, Chen Y, Lin Y.   +5 more
europepmc   +1 more source

A Retrospective Study of 19 Cases of Canine Myelofibrosis

, 2002
Douglas J. Weiss, Stephanie A. Smith
openalex   +1 more source

Valore predittivo di variabili clinico-laboratoristiche in pazienti con mielofibrosi trattati con inibitore di JAK-1/2 [PDF]

, 2011
CARAMAZZA, Domenica
core  

Spleen volume assessment in Ph-negative chronic myeloproliferative neoplasms: a real-life study comparing ultrasonography vs. magnetic resonance imaging scans. [PDF]

Ann Hematol
Pugliese N, Cavaliere C, Basso L, Fazio L, Malafronte R, Giordano C, Vincenzi A, Varricchio S, Mascolo M, Martinelli V, Picardi M, Salvatore M, Pane F.   +12 more
europepmc   +1 more source

Bone Marrow Involment and Myelofibrosis in Hudgkin's Disase

, 1998
Sare Kabukçuoğlu, Ülkü Öner, Zeki Üstüner, Serap Işıksoy, Emine Dündar, Nilüfer Tel   +5 more
openalex  

Cost-utility analysis of ropeginterferon alfa-2b to manage low-risk patients with polycythemia vera as compared to phlebotomy only in the Austrian healthcare system. [PDF]

Ann Hematol
Walter E, Torelli F, Barbui T.
europepmc   +1 more source

FDA greenlights momelotinib (Ojjaara) as the exclusive treatment for myelofibrosis patients battling anemia. [PDF]

Ann Med Surg (Lond)
Jehanzeb M, Iqbal U, Farhat N, Waseem R, Shahzad M, Mahmmoud Fadelallah Eljack M.   +5 more
europepmc   +1 more source

HMGA2 overexpression with specific chromosomal abnormalities predominate in CALR and ASXL1 mutated myelofibrosis. [PDF]

Leukemia
Handa S, Schaniel C, Tripodi J, Ahire D, Mia MB, Klingborg S, Tremblay D, Marcellino BK, Hoffman R, Najfeld V.   +9 more
europepmc   +1 more source